People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

were among the most effective treatments for treatment-resistant depression, usually defined as severe depressive symptoms that have not improved despite treatment with at least two standard ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...